AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33544305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886
Study 33544305 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 2886
Study 33166719 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off
Number of subjects: 59
Study 33017212 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet resection
Number of subjects: 104
Study 33017212 — intervention group
Group type: COMPARATOR
Intervention: Leaflet preservation
Number of subjects: 104
Study 35707974 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mL intravenous fluid bolus
Number of subjects: 1067
Study 35707974 — intervention group
Group type: COMPARATOR
Intervention: No fluid bolus
Number of subjects: 1067
Study 33657849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 1026
Study 33657849 — intervention group
Group type: COMPARATOR
Intervention: Combined Intravenous Thrombolysis (IVT) and Mechanical Thrombectomy (MT)
Number of subjects: 1026
Study 36405842 — intervention group
Group type: EXPERIMENTAL
Intervention: FTF/CD
Number of subjects: 110
Study 36405842 — intervention group
Group type: EXPERIMENTAL
Intervention: RD/CD
Number of subjects: 110
Study 36405842 — intervention group
Group type: EXPERIMENTAL
Intervention: RD/eSLD
Number of subjects: 110
Study 36405842 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 110
Study 32045493 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-079 (0.06 mg/kg i.v.)
Number of subjects: 74
Study 32045493 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-079 (0.6 mg/kg s.c.)
Number of subjects: 74
Study 32045493 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-079 (≥0.3 mg/kg s.c.)
Number of subjects: 74
Study 35122365 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-Spasticity App
Number of subjects: 115
Study 35122365 — intervention group
Group type: COMPARATOR
Intervention: Paper-based self-training program
Number of subjects: 115
Study 35122365 — intervention group
Group type: EXPERIMENTAL
Intervention: MIR
Number of subjects: 115
Study 33586924 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of mental exertion (EXP) by Stroop task
Number of subjects: 15
Study 33586924 — intervention group
Group type: COMPARATOR
Intervention: 30 minutes without mental exertion (CON)
Number of subjects: 15
Study 32946668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 29
Study 32946668 — intervention group
Group type: COMPARATOR
Intervention: Control (matched group who did not receive tocilizumab)
Number of subjects: 29
Study 36076211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg dose at enrolment)
Number of subjects: 1056
Study 36076211 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate (195 mg elemental iron daily, thrice daily from enrolment till 6 weeks postpartum)
Number of subjects: 1056
Study 34152835 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-Centered Spiritual Health Team Intervention (CCSH-TI)
Number of subjects: 41
Study 34152835 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 41
Study 32499262 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE intervention (individualised medication management, individual resiliency training, supported employment and education, family education)
Number of subjects: 400
Study 32499262 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE intervention
Number of subjects: 400
Study 35879178 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (5U/0.05 mL)
Number of subjects: 25
Study 35879178 — intervention group
Group type: COMPARATOR
Intervention: Lateral Tarsal Strip (LTS)
Number of subjects: 25
Study 32253271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV iron
Number of subjects: 2141
Study 32253271 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IV iron
Number of subjects: 2141
Study 34158778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 gr) over 30 minutes
Number of subjects: 60
Study 34158778 — intervention group
Group type: COMPARATOR
Intervention: Normal saline over 30 minutes (Control)
Number of subjects: 60
Study 32517660 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural rectal progesterone (800 mg daily)
Number of subjects: 199
Study 32517660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 34704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ageing awareness and high positive control (LAPC)
Number of subjects: 902
Study 34704645 — intervention group
Group type: EXPERIMENTAL
Intervention: High ageing awareness and negative control (HANC)
Number of subjects: 902
Study 34704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low positive consequences and control (LPCC)
Number of subjects: 902
Study 34987601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic elastography combined with HPV detection using the bilateral filter intelligent denoising algorithm
Number of subjects: 100
Study 34987601 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic elastography combined with HPV detection without optimization
Number of subjects: 100
Study 32202593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Disordered Breathing (SDB)
Number of subjects: 127
Study 34241801 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (FS Tablets, 0.9 g/d)
Number of subjects: 150
Study 34241801 — intervention group
Group type: COMPARATOR
Intervention: Combination of BYP and FS (BYP, 24 g/d plus FS Tablets, 0.9 g/d)
Number of subjects: 150
Study 32842249 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-tube epidural block group (n=108)
Number of subjects: 216
Study 32842249 — intervention group
Group type: COMPARATOR
Intervention: Single-tube epidural block group (n=108)
Number of subjects: 216
Study 35228755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab with CBM588
Number of subjects: 30
Study 35228755 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab without CBM588
Number of subjects: 30
Study 36047609 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation of foetal movement and position tracking
Number of subjects: 0
Study 36047609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 34531204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 60
Study 34531204 — intervention group
Group type: COMPARATOR
Intervention: Conventional AVR (mechanical vs stented or stentless bioprosthesis)
Number of subjects: 60
Study 36320165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical Association Technique
Number of subjects: 63
Study 36320165 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 63
Study 33852752 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine
Number of subjects: 45
Study 33852752 — intervention group
Group type: EXPERIMENTAL
Intervention: amantadine
Number of subjects: 45
Study 33852752 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 35235002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod-discontinuation group
Number of subjects: 20
Study 35235002 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod-continuation group
Number of subjects: 20
Study 35235002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 34591548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 88
Study 34591548 — intervention group
Group type: COMPARATOR
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 88
Study 34591548 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychodynamic therapy (SPT)
Number of subjects: 88
Study 34591548 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 88
Study 34328040 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar sender
Number of subjects: 0
Study 34328040 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar sender
Number of subjects: 0
Study 34328040 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar sender (nationwide survey)
Number of subjects: 0
Study 34328040 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar sender (nationwide survey)
Number of subjects: 0
Study 32319006 — intervention group
Group type: EXPERIMENTAL
Intervention: BZD tapering
Number of subjects: 84
Study 32319006 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical GHB tapering
Number of subjects: 84
Study 32233711 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary index score system
Number of subjects: 157
Study 35817643 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 117
Study 35817643 — intervention group
Group type: COMPARATOR
Intervention: minimal-dose rESWT
Number of subjects: 117
Study 34791307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 99
Study 34791307 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 99
Study 34791307 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin
Number of subjects: 99
Study 34791307 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 99
Study 34156308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollover abdominal paracentesis
Number of subjects: 0
Study 34156308 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal paracentesis
Number of subjects: 0
Study 33327260 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared irradiation (FIR) for 40 minutes
Number of subjects: 44
Study 33327260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 33382448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3×1000 mg/day, 0.5 mEq/kg)
Number of subjects: 45
Study 33382448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (2×1000 mg/day)
Number of subjects: 45
Study 33382448 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study 34864757 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Cognitive Training (20 hours total, 10 hours per two selected cognitive domains)
Number of subjects: 109
Study 34864757 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and delayed spatial learning and memory training
Number of subjects: 109
Study 34864757 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 109
Study 33060126 — intervention group
Group type: EXPERIMENTAL
Intervention: BATHE interview technique
Number of subjects: 138
Study 33060126 — intervention group
Group type: COMPARATOR
Intervention: Usual interview technique (Control)
Number of subjects: 138
Study 35146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video
Number of subjects: 135
Study 35146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Screencast
Number of subjects: 135
Study 35146628 — intervention group
Group type: COMPARATOR
Intervention: Text-based resource
Number of subjects: 135
Study 35775838 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated one-repetition maximum (1-RM)
Number of subjects: 177
Study 35775838 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic peak strength
Number of subjects: 177
Study 35775838 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 177
Study 35775838 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Up and Go test (GUG)
Number of subjects: 177
Study 35775838 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climb test
Number of subjects: 177
Study 34301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg) plus Erlotinib (150 mg/day)
Number of subjects: 0
Study 34301751 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (150 mg/day)
Number of subjects: 0
Study 34301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 0
Study 36371942 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural music
Number of subjects: 189
Study 36371942 — intervention group
Group type: COMPARATOR
Intervention: Plain music
Number of subjects: 189
Study 36371942 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 189
Study 33660178 — intervention group
Group type: EXPERIMENTAL
Intervention: Municipal wastewater (MW) irrigation
Number of subjects: 100
Study 33660178 — intervention group
Group type: EXPERIMENTAL
Intervention: Remediated wastewater (RW) irrigation
Number of subjects: 100
Study 33660178 — intervention group
Group type: COMPARATOR
Intervention: Tap water (TW) irrigation
Number of subjects: 100
Study 32074106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to attack advertisements
Number of subjects: 300
Study 36201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly TAS-102 (35 mg/m2 twice daily on days 1-5 and 15-19 in a 4-week cycle) and bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 44
Study 33856729 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (30 g/day ground flaxseed powder)
Number of subjects: 70
Study 33255561 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of docosahexaenoic acid (DHA) during pregnancy
Number of subjects: 0
Study 33255561 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DHA intake during the third trimester
Number of subjects: 0
Study 33255561 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DHA intake during gestation and lactation
Number of subjects: 0
Study 35192645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 35
Study 35192645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 35
Study 33180211 — intervention group
Group type: EXPERIMENTAL
Intervention: Productive failure learning condition
Number of subjects: 42
Study 33180211 — intervention group
Group type: COMPARATOR
Intervention: Indirect failure learning condition
Number of subjects: 42
Study 33334158 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐led Group Lifestyle Balance (PGLB) intervention
Number of subjects: 314
Study 33334158 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 32476236 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated sodium butyrate (BLM)
Number of subjects: 49
Study 32476236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 32576131 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion 0.25 μg/kg/min
Number of subjects: 180
Study 32576131 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion 1ug/kg/min with propofol 50-150 ug/kg/min
Number of subjects: 180
Study 33135384 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS method with direct dilute and shoot analysis
Number of subjects: 0
Study 33135384 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS method after glucuronide hydrolysis
Number of subjects: 0
Study 36056577 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA < 1 ng/mL
Number of subjects: 0
Study 36056577 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 1.0-1.99 ng/mL
Number of subjects: 0
Study 36056577 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 2-2.99 ng/mL
Number of subjects: 0
Study 36056577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratification and re-screening intervals
Number of subjects: 0
Study 33540206 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Disclosure (AD)
Number of subjects: 122
Study 33540206 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy – Cognitive Therapy version (CPT-C)
Number of subjects: 122
Study 35555185 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (50 mg/kg/day)
Number of subjects: 64
Study 35555185 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 64
Study 32757413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (median dose = 0.75 mg)
Number of subjects: 47
Study 32757413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32757413 — intervention group
Group type: COMPARATOR
Intervention: Comparison between nabilone and placebo
Number of subjects: 47
Study 35854238 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling (up to six proactive phone calls over approximately six weeks)
Number of subjects: 910
Study 35854238 — intervention group
Group type: COMPARATOR
Intervention: Self-help brochure (control condition)
Number of subjects: 910
Study 35854238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 910
Study 35854238 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-abstainers
Number of subjects: 910
Study 34111359 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) services, 10 home visits
Number of subjects: 223
Study 34111359 — intervention group
Group type: COMPARATOR
Intervention: Certified Asthma Educator (AE‐C) services, 2 in-clinic sessions
Number of subjects: 223
Study 32928286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic polyurethane PICC with proximal valve
Number of subjects: 111
Study 32928286 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane PICC with external clamp (standard care)
Number of subjects: 111
Study 35487685 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (sNfL) levels at baseline
Number of subjects: 51
Study 35487685 — intervention group
Group type: EXPERIMENTAL
Intervention: Age/body mass index-adjusted sNfL Z-scores
Number of subjects: 51
Study 35487685 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 5.1 pg/mL in sNfL levels between baseline and 6 years
Number of subjects: 51
Study 34932107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorgan focused clinical ultrasonography (FCU) performed by an internal medicine physician in addition to standard clinical evaluation
Number of subjects: 248
Study 34932107 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical evaluation (Control)
Number of subjects: 248
Study 34932107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorgan focused clinical ultrasonography (FCU)
Number of subjects: 248
Study 35435074 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Care students as full-time interdisciplinary team members during 12-week placements
Number of subjects: 16
Study 33197395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 1132
Study 33197395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study 33144354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose treatment
Number of subjects: 7275
Study 33144354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) intervention
Number of subjects: 7275
Study 33144354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 7275
Study 32052592 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachio-basilic upper arm transposition fistula (BBAVF)
Number of subjects: 60
Study 32052592 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic brachio-axillary vascular access grafts (BAPTFE)
Number of subjects: 60
Study 2011528253 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic infrared energy (MIRE) therapy, daily for a total of 12 treatments
Number of subjects: 24
Study 2011528253 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study 35537502 — intervention group
Group type: EXPERIMENTAL
Intervention: T2HIGH/T17LOW
Number of subjects: 70
Study 35537502 — intervention group
Group type: EXPERIMENTAL
Intervention: T2LOW/T17HIGH
Number of subjects: 70
Study 35537502 — intervention group
Group type: EXPERIMENTAL
Intervention: High FeNO levels
Number of subjects: 70
Study 35537502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin SN (CST1)
Number of subjects: 70
Study 33486203 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of MeSCL30 in Arabidopsis
Number of subjects: 15
Study 33486203 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative splicing in cassava genes
Number of subjects: 15
Study 32309857 — intervention group
Group type: EXPERIMENTAL
Intervention: HP rs2000999 G allele
Number of subjects: 540
Study 32309857 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin level genetically predicted by HP rs2000999
Number of subjects: 540
Study 34338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 105 CFU/kg
Number of subjects: 2400
Study 34338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 106 CFU/kg
Number of subjects: 2400
Study 34338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 107 CFU/kg
Number of subjects: 2400
Study 34338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 108 CFU/kg
Number of subjects: 2400
Study 34338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Number of subjects: 2400
Study 34338348 — intervention group
Group type: COMPARATOR
Intervention: Control group (basal diet)
Number of subjects: 2400
Study 34010530 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 300
Study 34010530 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 300
Study 32779141 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders with medication treatment
Number of subjects: 352
Study 32779141 — intervention group
Group type: COMPARATOR
Intervention: Control group with 4-week medication treatment without reminders
Number of subjects: 352
Study 36264431 — intervention group
Group type: COMPARATOR
Intervention: CRADLE trial cohort (n = 54)
Number of subjects: 554
Study 33033864 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer genetically predicted telomeres
Number of subjects: 417772
Study 33033864 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Egger regression, weighted median, and weighted mode approaches
Number of subjects: 417772
Study 33033864 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Egger regression
Number of subjects: 417772